BioCentury | Jun 27, 2020
Deals

Why the WuXi NextCode split makes strategic sense for the multinational genomics company

WuXi NextCode’s move to split its China business from operations in the U.S. and Europe seems like the best path forward for both entities, as each faces tightening regulations that restrict the flow of genomic...
BC Innovations | Oct 11, 2018
Strategy

Border security for China’s genomes

China’s policies on sharing genomic data have so far produced cumbersome but manageable hurdles for cross-border clinical trials and translational research. But the explosive growth of its genomics industry, and the backdrop of rising political...
BC Innovations | Sep 21, 2018
Product R&D

China’s rising genomics start-ups

Behind bellwethers BGI Genomics Co. Ltd. and WuXi NextCode Genomics Inc., a new generation of Chinese genomics companies is emerging with ambitions to solve urgent problems, including early cancer detection and clinical trial recruitment, by...
BC Extra | Jul 11, 2018
Company News

Ally Bridge invests in Tasly Biopharmaceuticals

Tasly Biopharmaceuticals Co. Ltd. (Shanghai, China) said Wednesday it issued 75.7 million new shares, representing about 7% of the company, as it prepares for a possible IPO. The investors, which include Ally Bridge LB Healthcare...
BC Week In Review | May 11, 2018
Financial News

WuXi AppTec prices Shanghai IPO

Services and manufacturing company WuXi AppTec Co. Ltd. (Shanghai:603259) raised RMB2.3 billion ($354 million) on May 7 through the sale of 104.2 million shares at RMB21.60 in an IPO underwritten by Huatai and Guotai Junan....
BC Extra | May 7, 2018
Financial News

WuXi AppTec prices Shanghai IPO

Services and manufacturing company WuXi AppTec Co. Ltd. (Shanghai:603259) raised RMB2.3 billion ($354 million) through the sale of 104.2 million shares at RMB21.60 in an IPO underwritten by Huatai and Guotai Junan. The price values...
BC Week In Review | Apr 13, 2018
Financial News

Unity proposes $85M IPO

On April 5, Unity Biotechnology Inc. (Brisbane, Calif.) filed to raise up to $85 million in an IPO on NASDAQ underwritten by Goldman Sachs, Morgan Stanley, Citigroup and Mizuho. Unity's lead candidates target senescent cells...
BC Extra | Apr 6, 2018
Financial News

Age-related disease play Unity planning IPO

Unity Biotechnology Inc. (Brisbane, Calif.) filed to raise up to $85 million in an IPO on NASDAQ underwritten by Goldman Sachs, Morgan Stanley, Citigroup and Mizuho. Unity's lead candidates target senescent cells to treat age-related...
BioCentury | Apr 2, 2018
Finance

Maintaining Moderna

A rumored dual listing on the Hong Kong stock exchange and NASDAQ could enable Moderna Therapeutics Inc. to maintain its ballooning valuation as it enters the public market. The mRNA play has raised $1.6 billion...
BC Week In Review | Mar 30, 2018
Financial News

Wuxi AppTec to raise $907.5M on Shanghai Stock Exchange

The WuXi AppTec services and manufacturing unit of New WuXi Life Science Ltd. (Shanghai, China) received approval from the China Securities Regulatory Commission to list on the Shanghai Stock Exchange. According to a February prospectus,...
Items per page:
1 - 10 of 200
BioCentury | Jun 27, 2020
Deals

Why the WuXi NextCode split makes strategic sense for the multinational genomics company

WuXi NextCode’s move to split its China business from operations in the U.S. and Europe seems like the best path forward for both entities, as each faces tightening regulations that restrict the flow of genomic...
BC Innovations | Oct 11, 2018
Strategy

Border security for China’s genomes

China’s policies on sharing genomic data have so far produced cumbersome but manageable hurdles for cross-border clinical trials and translational research. But the explosive growth of its genomics industry, and the backdrop of rising political...
BC Innovations | Sep 21, 2018
Product R&D

China’s rising genomics start-ups

Behind bellwethers BGI Genomics Co. Ltd. and WuXi NextCode Genomics Inc., a new generation of Chinese genomics companies is emerging with ambitions to solve urgent problems, including early cancer detection and clinical trial recruitment, by...
BC Extra | Jul 11, 2018
Company News

Ally Bridge invests in Tasly Biopharmaceuticals

Tasly Biopharmaceuticals Co. Ltd. (Shanghai, China) said Wednesday it issued 75.7 million new shares, representing about 7% of the company, as it prepares for a possible IPO. The investors, which include Ally Bridge LB Healthcare...
BC Week In Review | May 11, 2018
Financial News

WuXi AppTec prices Shanghai IPO

Services and manufacturing company WuXi AppTec Co. Ltd. (Shanghai:603259) raised RMB2.3 billion ($354 million) on May 7 through the sale of 104.2 million shares at RMB21.60 in an IPO underwritten by Huatai and Guotai Junan....
BC Extra | May 7, 2018
Financial News

WuXi AppTec prices Shanghai IPO

Services and manufacturing company WuXi AppTec Co. Ltd. (Shanghai:603259) raised RMB2.3 billion ($354 million) through the sale of 104.2 million shares at RMB21.60 in an IPO underwritten by Huatai and Guotai Junan. The price values...
BC Week In Review | Apr 13, 2018
Financial News

Unity proposes $85M IPO

On April 5, Unity Biotechnology Inc. (Brisbane, Calif.) filed to raise up to $85 million in an IPO on NASDAQ underwritten by Goldman Sachs, Morgan Stanley, Citigroup and Mizuho. Unity's lead candidates target senescent cells...
BC Extra | Apr 6, 2018
Financial News

Age-related disease play Unity planning IPO

Unity Biotechnology Inc. (Brisbane, Calif.) filed to raise up to $85 million in an IPO on NASDAQ underwritten by Goldman Sachs, Morgan Stanley, Citigroup and Mizuho. Unity's lead candidates target senescent cells to treat age-related...
BioCentury | Apr 2, 2018
Finance

Maintaining Moderna

A rumored dual listing on the Hong Kong stock exchange and NASDAQ could enable Moderna Therapeutics Inc. to maintain its ballooning valuation as it enters the public market. The mRNA play has raised $1.6 billion...
BC Week In Review | Mar 30, 2018
Financial News

Wuxi AppTec to raise $907.5M on Shanghai Stock Exchange

The WuXi AppTec services and manufacturing unit of New WuXi Life Science Ltd. (Shanghai, China) received approval from the China Securities Regulatory Commission to list on the Shanghai Stock Exchange. According to a February prospectus,...
Items per page:
1 - 10 of 200